Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Evolocumab, a PCSK9 inhibitor, is approved for lowering LDL cholesterol in pediatric patients with familial hypercholesterolemia (FH).
• Cognitive safety of evolocumab is established in adults but not yet in pediatric populations.
• Familial hypercholesterolemia (FH) is a genetic disorder leading to high LDL cholesterol levels.

Purpose of the Study:

• To assess the impact of evolocumab on cognitive function in pediatric patients with heterozygous FH.
• To evaluate the cognitive safety of evolocumab in a pediatric FH cohort.

Main Methods:

• A 24-week, randomized, double-blind, placebo-controlled study (HAUSER-RCT) was conducted.
• Cognitive function was assessed using tests for psychomotor function, attention, visual learning, and executive function.
• Statistical analyses included ANCOVA, Cohen's d, and reliable change indices to compare treatment groups.

Main Results:

• Cognitive test score changes from baseline were comparable between the evolocumab and placebo groups at 24 weeks.
• Specific test score differences (95% CI) included: Groton Maze Learning 0.1 (-0.2, 0.4), One-Card Learning -0.1 (-0.5, 0.4), Identification 0.3 (0.0, 0.7), and Detection 0.3 (-0.1, 0.8).
• Clinically significant cognitive decline occurred less frequently in the evolocumab group.

Conclusions:

• Evolocumab treatment for 24 weeks demonstrated no adverse effects on cognitive function in pediatric patients with FH.
• The study supports the cognitive safety profile of evolocumab in this young population.
• Further long-term studies may be warranted to confirm sustained cognitive safety.